Kronik Santral Seröz Koryoretinopatide Fotodinamik Tedavinin ve İntravitreal Bevacizumab Enjeksiyonunun Etkinliği

Hasan Ali Tufan; Metin Ünlü; Sedat Arıkan; Selçuk Kara; Baran Gencer; Şengül Özdek

doi:10.5505/abantmedj.2014.42104

Efficacy of Photodynamic Therapy Versus Intravitreal Bevacizumab Injection for Chronic Central Serous Chorioretinopathy

Year 2014, , 1 - 6, 01.01.2014

Hasan Ali Tufan Metin Ünlü Sedat Arıkan Selçuk Kara Baran Gencer Şengül Özdek

https://doi.org/10.5505/abantmedj.2014.42104

Abstract

Objective: To compare the efficacy of photodynamic therapy PDT versus intravitreal bevacizumab IVB injection for the treatment of chronic central serous chorioretinopathy CSC . Method: The medical records of 16 eyes of 15 patients who received PDT n=9 or IVB n=6 for symptomatic chronic central serous chorioretinopathy CSC were retrospectively reviewed. Best-corrected visual acuity BCVA , central macular thickness CMT , and subretinal fluid SRF volume were compared between the two patient groups at baseline and at 1,3 and 6 months after treatment. Results: Median BCVA was similar in both groups at all time points p>0.05 . The reduction of CMT was significant at the 1st and 3rd month p

Keywords

Chronic central serous chorioretinopathy, photodynamic therapy, intravitreal bevacizumab

References

1. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126–145.
2. Lida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 1999; 19:.508–512.
3. Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 709–712.
4. Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K. Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992; 2: 103– 114.
5. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997; 104: 616–622.
6. Parodi MB, Pozzo SD, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003; 23: 235–237.
7. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM Jr, Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288–298.
8. Moon JW, Yu HG, Kim TW, Kim HC, Chung H. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1315–1323.
9. Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009; 53:52–56.
10. Gregori-Gisbert I, Aguirre-Balsalobre F, García-Sánchez J, León-Salvatierra G, MengualVerdú E, Hueso-Abancéns JR Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection. Arch Soc Esp Oftalmol 2011; 86: 407-411.
11. Lim SJ, Roh MI, Kwon OW Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2009; 30: 100–106.
12. Torres-Soriano ME, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, AbrahamMarín M, Ober MD et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 2008; 246: 1235-1239.
13. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 2009; 19: 613-617.
14. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. – Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541–560.
15. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109: 1723–1725.
16. Caccavale A, Imparato M, Romanazzi F, Negri A, Porta A, Ferentini F. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses 2009; 73: 435-437.
17. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina 2011; 31: 766-771.
18. Piccolino CF, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752–763.
19. Ruiz-Moreno JM, Lugo FL, Armadá F, Silva R, Montero JA, Arevalo JF, Arias L, GómezUlla F. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 2010; 88: 371–376.
20. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006; 90: 869–874.
21. Shin JY, Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2010; 31: 119–126.
22. Niegel MF, Schrage NF, Christmann S. Degenring RF. Intravitreal bevacizumab for chronic central serous chorioretinopathy. Ophthalmology 2008; 105: 943-945.
23. Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012; 56: 608-612.